Smith Kline & French Laboratories, Ltd. vs. Court of Appeals

A compulsory license may be granted over a patented pharmaceutical product necessary for public health under Section 34(1)(e) of the Patent Law, as this constitutes a valid exercise of police power to prevent patent monopolies and is consistent with the Paris Convention.

Petitioner is the assignee of Letters Patent No. 12207 covering Cimetidine, a pharmaceutical product used as an antihistamine and for ulcer treatment, issued in 1978. Over a decade after the patent's issuance, private respondent sought a compulsory license to manufacture and sell medicines containing the same active ingredient, invoking the public health provisions of the Patent Law.

• The Patent: Petitioner is the assignee of Letters Patent No. 12207, issued on November 29, 1978, covering the pharmaceutical product Cimetidine, which is useful as an antihistamine and in the treatment of ulcers.
• The Application for Compulsory License: On August 21, 1989, private respondent Danlex Research Laboratories, Inc. filed a petition with the BPTTT for a compulsory license to manufacture and produce its own brand of medicines using Cimetidine. The petition invoked Section 34(1)(e) of Republic Act No. 165, as amended, which allows compulsory licensing if the patented article relates to medicine or is necessary for public health or safety, provided the applicant proves its capability to work the patented product.
• Opposition to the Application: Petitioner opposed the application, contending that private respondent had no cause of action, failed to allege how it intended to work the patent, and that petitioner's own manufacture and sales already satisfied Philippine market needs. Petitioner further claimed the grant would not promote public safety and that private respondent was motivated purely by pecuniary gain.
• BPTTT Ruling: After hearing both parties, the BPTTT directed the issuance of a compulsory license to private respondent to use, manufacture, and sell pharmaceutical products containing Cimetidine in the Philippines. The BPTTT ordered private respondent to pay petitioner royalties at the rate of 2.5% of net sales in Philippine currency.

• Invalid Exercise of Police Power: Petitioner maintained that the grant of a compulsory license constitutes an invalid exercise of police power because there is no overwhelming public necessity, given that petitioner adequately supplies the Philippine market. Such a grant unjustly deprives petitioner of a reasonable return on its investment.
• Violation of the Paris Convention: Petitioner argued that Section 34 of the Patent Law contravenes the Paris Convention for the Protection of Industrial Property, which allegedly permits compulsory licenses only to prevent abuses resulting from exclusive rights, such as failure to work the patent within a specific period.
• Confusion of Source: Petitioner contended that the compulsory license would mislead the public into believing that Cimetidine is the invention of private respondent, thereby diluting petitioner's patent rights.
• Unjust Compensation: Petitioner asseverated that the 2.5% royalty rate fixed by the BPTTT is grossly inadequate and lacks factual basis, amounting to an expropriation of private property without just compensation, considering petitioner's huge investments in research, development, and marketing.
• Lack of Jurisdiction: Petitioner claimed the BPTTT never acquired jurisdiction over the petition because private respondent failed to formally offer proof of compliance with the jurisdictional requirement of publication under Section 35-F of the Patent Law.

• Adoption of Appellate Court Ruling: Respondent adopted the reasoning of the Court of Appeals, which affirmed that the compulsory license is in accord with the Patent Law given the medicinal nature of the product, that the law intends to prevent patent monopolies, that the 2.5% royalty rate is reasonable for a bare license without technical assistance, and that proof of publication had been submitted.

• Validity of Police Power Exercise: Whether the grant of a compulsory license over a patented medicine constitutes a valid exercise of police power despite the patentee providing an adequate supply to the market.
• Consistency with the Paris Convention: Whether Section 34(1)(e) of the Patent Law contravenes the Philippines' treaty obligations under the Paris Convention for the Protection of Industrial Property.
• Adequacy of Royalty Rate: Whether the 2.5% royalty rate fixed by the BPTTT constitutes a deprivation of property without just compensation.
• Compliance with Publication Requirement: Whether the BPTTT acquired jurisdiction given the alleged failure of private respondent to comply with the publication requirement.

• Validity of Police Power Exercise: The grant of the compulsory license was upheld as a valid exercise of police power. More than ten years had passed since the patent was issued, the product is medicinal, and private respondent's capability to work the product was established. The legislative intent behind Section 34 is not merely to ensure supply but to prevent the growth of monopolies.
• Consistency with the Paris Convention: No inconsistency exists between Section 34 of the Patent Law and the Paris Convention. Article 5, Section A(2) of the Convention explicitly respects the right of member countries to adopt legislative measures providing for compulsory licenses to prevent abuses resulting from exclusive patent rights. "Failure to work" is merely an example of such abuse; the treaty does not preclude other categories, such as the growth of monopolies, which Congress sought to prevent.
• Adequacy of Royalty Rate: The 2.5% royalty rate was affirmed as reasonable and not constitutive of uncompensated taking. Petitioner had already enjoyed exclusive rights for over two years and continues to receive remuneration via royalties. The rate falls well within the 5% ceiling prescribed by Section 35-B(3) of the Patent Law. Furthermore, the rate applies to a bare license without technical assistance from the licensor, and factual findings of administrative bodies on such matters are accorded finality if supported by substantial evidence.
• Compliance with Publication Requirement: Petitioner was estopped from questioning the BPTTT's jurisdiction based on defective publication. The issue was raised for the first time on appeal to the Court of Appeals, not during the hearings before the BPTTT.

• Compulsory Licensing as Police Power — The State, in the exercise of police power, may grant compulsory licenses over patented medicines to prevent monopolies and promote public health, even if the patentee is adequately supplying the market. The right to exclusive use is subject to the paramount right of the State to prevent abuses.
• Interpretation of the Paris Convention on Compulsory Licensing — Article 5, Section A(2) of the Paris Convention allows member countries to legislate compulsory licenses to prevent abuses of patent rights. "Failure to work" is merely an illustrative example of abuse, not an exclusive ground; the prevention of monopolies falls within the permissible legislative measures.
• Finality of Administrative Findings of Fact — Factual findings of administrative bodies, who are considered experts in their respective fields, are accorded not only respect but finality if supported by substantial evidence.
• Estoppel from Questioning Jurisdiction — A party who actively participates in administrative proceedings without objecting to jurisdictional defects, such as lack of publication, is estopped from raising such defects for the first time on appeal.

• "It is thus clear that Section A(2) of Article 5 [of the Paris Convention] unequivocally and explicitly respects the right of member countries to adopt legislative measures to provide for the grant of compulsory licenses to prevent abuses which might result from the exercise of the exclusive rights conferred by the patent. An example provided of possible abuses is 'failure to work;' however, as such, is merely supplied by way of an example, it is plain that the treaty does not preclude the inclusion of other forms of categories of abuses."
• "Certainly, the growth of monopolies was among the abuses which Section A, Article 5 of the Convention foresaw, and which our Congress likewise wished to prevent in enacting R.A. No. 165."
• "Even assuming arguendo that such confusion may indeed occur, the disadvantage is far outweighed by the benefits resulting from the grant of the compulsory license, such as an increased supply of pharmaceutical products containing Cimetidine, and the consequent reduction in the prices thereof."

• Smith Kline & French Laboratories, Ltd. vs. Court of Appeals, 276 SCRA 224 (1997) — Controlling precedent directly on point, where the Court previously ruled that Section 34 of the Patent Law is consistent with the Paris Convention and that preventing monopolies is a recognized abuse under the treaty.
• Price vs. United Laboratories, 166 SCRA 133 (1988) — Followed to support the reasonableness of the 2.5% royalty rate for a bare license without technical assistance, and to note that identical rates have been prescribed in numerous patent cases.
• Parke Davis & Co. vs. Doctors' Pharmaceuticals, Inc., 14 SCRA 1053 (1965) — Cited for the proposition that the benefits of compulsory licensing, such as increased supply and reduced prices, outweigh potential confusion regarding the source of the invention.
• Golden Thread Knitting Industries, Inc. vs. National Labor Relations Commission, 304 SCRA 568 (1999) — Cited for the doctrine that factual findings of administrative bodies are accorded finality if supported by substantial evidence.

• Section 34(1)(e), Republic Act No. 165 (The Patent Law) — Provides that any person may apply for a compulsory license after two years from the grant of the patent if the patented invention relates to food or medicine, or is necessary for public health or public safety. Applied as the direct statutory basis for granting the compulsory license to private respondent.
• Section 35-B(3), Republic Act No. 165 — Stipulates that royalty payments under a compulsory license shall not exceed five percent (5%) of the net wholesale price of the products manufactured under the license. Applied to validate the 2.5% royalty rate fixed by the BPTTT as it falls within the statutory ceiling.
• Article 5, Section A(2), Paris Convention for the Protection of Industrial Property — Reserves the right of member countries to take legislative measures providing for the grant of compulsory licenses to prevent abuses resulting from the exclusive rights conferred by a patent. Interpreted to mean that "failure to work" is merely an example of abuse, thus harmonizing the treaty with the broader grounds provided under Section 34 of the Patent Law.

Davide, Jr., C.J. (Chairman), Puno, Pardo, and Ynares-Santiago, JJ.